Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy

This study has been completed.
Information provided by:
Novartis Identifier:
First received: April 21, 2007
Last updated: February 3, 2011
Last verified: February 2011
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):